| 325 Mdg | |
|
325 Mdg Bldg 1305 Suwannee Ave Tyndall Afb FL 32403 | |
| (850) 283-7511 | |
| (850) 283-7721 |
| Full Name | 325 Mdg |
|---|---|
| Speciality | Psychologist |
| Location | 325 Mdg Bldg, Tyndall Afb, Florida |
| Authorized Official Name and Position | George Nicholas (325 MDG COMMANDER) |
| Authorized Official Contact | 8502837515 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| 325 Mdg 2405 Maple Ct Panama City FL 32404-3047 Ph: (850) 283-7511 | 325 Mdg 325 Mdg Bldg 1305 Suwannee Ave Tyndall Afb FL 32403 Ph: (850) 283-7511 |
| NPI Number | 1568436962 |
|---|---|
| Provider Enumeration Date | 02/14/2006 |
| Last Update Date | 06/13/2008 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568436962 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PY5848 (Florida) | Primary |
News Archive
Orthovita, Inc., an orthobiologics and biosurgery company, reported financial results for the quarter ended June 30, 2010. Product sales for the second quarter of 2010 were $23.9 million compared to $24.5 million for the second quarter of 2009. Product sales for the second quarter of 2009 included $0.6 million from the sale of Vitomatrix™, a bone graft material used in dental products. There were no Vitomatrix sales in the second quarter of 2010 and no further sales of Vitomatrix are currently expected.
Vangard Voice Systems, Inc. (Vangard), the innovative provider of the AccuSpeech® Mobile Voice Platform (MVP) which adds high productivity voice-direct capabilities to existing mobile applications, announced a partnership with Vista LifeSciences to voice-enable Vista LifeSciences' medical assessment and clinical encounter/medical record products.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Piperacillin and Tazobactam for Injection, the number one prescribed intravenous antibiotic in the U.S. APP will launch the product immediately.
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.
› Verified 9 days ago